3.3. Transcriptomic Analysis Revealed a Distinct Response Pattern in a Subset of the Patients
MINOR
Next, we investigated subject similarities across the dataset and applied hierarchical clustering using a multiscale bootstrap resampling of the 1500 most variable genes across all samples treated with 600 µg/kg or 900 µg/kg mitazalimab at C1D1, C1D2, and C3D1. By doing so, a significant cluster of 10 patients (named patient group 1) that had received mitazalimab at either 600 µg/kg or 900 µg/kg was apparent (Mitazalimab was found to have a more pronounced effect on the peripheral transcriptome of patient group 1 than on that of patient group 2, with 1610 and 237 DEGs in the respective group (To further evaluate the differences in immune responses between the groups, we first compared the expression of genes related to the regulation of interferon responses, by utilizing gene signatures previously identified in interferon-stimulated monocytes [Next, we evaluated how the stratification based on transcriptomic profiles translated into blood cytokine levels. Following mitazalimab treatment, patients in group 1 seemed to have higher levels of IP-10, MCP-1, MIP-1α, and MIP-1β than those in group 2, who had higher levels of IL-10 (The analysis of baseline transcriptomic profiles in the two groups showed minor differences, mainly attributed to increased expression of ribosomal protein in group 2 (